Kronos Bio’s KB-7898 reduces pathological scores in inflammatory disorders

Dec. 4, 2024

Kronos Bio Inc. has presented data on KB-7898, an orally available p300 KAT inhibitor.

Cancer

Kronos Bio nominates development candidate for multiple myeloma

Dec. 19, 2023

Kronos Bio Inc. has nominated a new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 transcription regulatory network (TRN), which is a key driver in multiple myeloma.

Today's news in brief

BioWorld

BioWorld briefs for Jan 21, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 21, 2026.

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...